Antimalarial drugs: Pharmacology, pharmacokinetics and toxicity;Les antimalariques: Pharmacologie, pharmacocinetique et toxicite chez l'adulte

Medecine et Maladies Infectieuses

Volumn 29, Issue SUPPL. 2, 1999, Pages

  Lebrun Vignes, B ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antimalarial drugs; Pharmacokinetics; Plasmodium falciparum; Toxicity

Indexed keywords

ANTIMALARIAL AGENT; ARSIQUINOFORME; ARTEMISININ; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; LAFRAN; MEFLOQUINE; PROGUANIL; QUINIMAX; QUININE; QUINOFORME; UNCLASSIFIED DRUG; ZAVARINE;

CARDIOTOXICITY; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; EYE TOXICITY; FRANCE; HUMAN; INFECTION PREVENTION; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; RISK BENEFIT ANALYSIS; SKIN TOXICITY;

EID: 0032804610     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(00)87134-6     Document Type: Conference Paper

References (72)

1. Legros F, Gay F, Belkaid M, Danis M. Paludisme en France métropolitaine en 1996. Bulletin CNRMI n° 13 ; juillet 1997.
2. Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance. Int J Parasitol 1997 ; 27 : 231-40.
3. Tracy JW, Webster LT. Drugs used in the chemotherapy of protozoal infections. Malaria. In: Hardman JG, Limbird LE. Goodman and Gilman's. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 965-85.
4. Le Bras J, Longuet C, Charmot G. Transmission humaine et résistance des plasmodies. Rev Prat 1998 ; 48 : 287-90.
5. Vidal® 1998, le dictionnaire. Paris : Éditions du Vidal® ; 1998.
6. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996 ; 31 : 257-74.
7. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996 ; 30 : 263-99.
8. Wetsteyn JC, De Vries PJ, Oosterhuis B, Van Boxtel CJ. The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br J Clin Pharmacol 1995 ; 39 : 696-9.
9. Fadeke Aderounmu A, Salako LA, Lindström B, Walker O, Ekman L. Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans. Br J Clin Pharmacol 1986; 22: 559-64.
10. Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983 ; 15 : 471-9.
11. Tett SE, Cutler DJ. Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur J Clin Pharmacol 1987 ; 31 : 729-31.
12. Luzzi GA, Peto TE. Adverse effects of antimalarials. An update. Drug Saf 1993 ; 4 : 295-311.
13. Tester-Dalderup CBM. Antiprotozoal drugs-antimalarial drugs. In: Dukes MNG. Meyler's side effects of drugs. An encyclopedia of adverse reactions and interactions. 13th ed. Amsterdam: Elsevier ; 1996.
14. Stockley H. Drug Interactions. A source book of adverse interactions, their mechanisms, clinical importance and management. 3rd ed. London: Blackwell Scientific Publications; 1994.
15. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985 ; 10 : 187-215.
16. White NJ. The treatment of malaria. N Engl J Med 1996 ; 335 : 800-6.
17. Claessen FA, Van Boxel CJ, Perenboom RM, Tange RA, Wetsteyn JC, Kager PA. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy caucasian subjects and in patients with falciparum malaria. Trop Med Int Health 1998 ; 3 : 482-9.
18. Sowunmi A, Salako LA. Effect of dose size on the pharmacokinetics of orally administered quinine. Eur J Clin Pharmacol 1996 ; 49 : 383-6.
19. Jamaludin A, Mohamad M. Navaratnam V, Selliah K, Tan SC, Wernsdorfer WH, et al. Relative bioavailability of the hydrochloride, sulphate and ethylcarbonate salts of quinine. Br J Clin Pharmacol 1988 ; 25 : 261-3.
20. Salako LA, Sowunmi A. Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. Eur J Clin Pharmacol 1992 ; 42 : 171-4.
21. White NJ, Chanthavanich P, Krishna S, Bunch C, Silamut K. Quinine disposition kinetics. Br J Clin Pharmacol 1983 ; 16 : 399-403.
22. Wanwimolruk S, Chalcroft S. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. Br J Clin Pharmacol 1991 ; 32 : 617-20.
23. Supanaranond W, Davis TME, Pukrittayakamee S, Silamut K, Karbwang J, Molunto P, et al. Disposition of oral quinine in acute falciparum malaria. Eur J Clin Pharmacol 1991 ; 40 : 49-52.
24. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am J Med 1982 ; 73 : 564-72.
25. White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol 1992 ; 34 : 1-10.
26. Silamut K, Molunto P, Ho M, Davis TME, White NJ. α1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol 1991 ; 32 : 311-5.
27. Davis TME, Supanaranond W, Pukrittayakamee S, Karbwang J, Molunto P, Mekthon S, et al. A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. J Infect Dis 1990 ; 161 ; 1305-8.
28. Rimchala P, Karbwang J, Sukontason K, Banmeruroi V, Molunto P, Na-Bangchang K. Pharmacokinetics of quinine in patients with chronic renal failure. Eur J Clin Pharmacol 1996; 49 : 497-501.
29. Karbwang J, Thanavibul A, Molunto P, Na Bangchang K. The pharmacokinetics of quinine in patients with hepatitis. Br J Clin Pharmacol 1993 ; 35 : 444-6.
30. Auprayoon P, Sukontason K, Na-Bangchang K, Banmairuroi V, Molunto P Karbwang J. Pharmacokinetics of quinine in chronic liver disease. Br J Clin Pharmacol 1995 ; 40 : 494-7.
31. Dyson EH, Proudfoot AT, Prescott LF, Heyworth R. Death and blindness due to overdose of quinine. Br Med J 1985 ; 291 : 31-3.
32. Vachon F. Résurgence de la fièvre bilieuse hémoglobinurique. Rev Prat 1998 ; 48 : 284.
33. Wanwimolruk S, Sunbhanich M, Pongmarutai M, Patamasucon P. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine. Br J Clin Pharmacol 1986 ; 22 : 346-50.
34. Wanwimolruk S, Kaewvichit S, Tanthayaphinant O, Sunwannarach C, Oranratnachai A. Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. Br J Clin Pharmacol 1991 ; 31 : 179-81.
35. Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993 ; 45 : 430-75.
36. Karbwang J, Na-Bangchang K. Clinical application of mefloquine pharmacokinetics in the treatment of Plasmodium falciparum malaria. Fundam Clin Pharmacol 1994 ; 8 : 491-502.
37. Crevoisier C, Handschin J, Barre J, Roumenov D, Kleinbloesem C. Food increases the bioavailability of the mefloquine. Eur J Clin Pharmacol 1997 ; 53 : 135-9.
38. Gimenez F, Pennie RA, Koren G, Crevoisier C, Wainer IW, Farinotti R. Stereoselective pharmacokinetics of mefloquine in healthy caucasians after multiple doses. J Pharm Sci 1994 ; 83 : 824-7.
39. Martin C, Gimenez F, Bangchang KN, Karbwang J, Wainer IW, Farinotti R. Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. Eur J Clin Pharmacol 1994 ; 47 : 85-7.
40. Hellgren U, Berggren-Palme I, Bergqvist Y, Jerling M. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. Br J Clin Pharmacol 1997 ; 44: 119-24.
41. Na-Bangchang K, Molunto P, Banmairuroi V, Thanavibul A, Karbwang J. Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. Int J Clin Pharmacol Res 1995 ; 15 : 215-20.
42. Juma FD, Ogeto JO. Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. Eur J Drug Metab Pharmacokinet 1989 ; 14 : 15-7.
43. Na-Bangchang K, Davis TM, Looareesuwan S, White NJ, Bunnag D, Karbwang J. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg 1994 ; 88 : 321-3.
44. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. Br Med J 1996; 313 : 525-8.
45. Karbwang J, Na-Bangchang K, Thanavibul A, Back TJ, Bunnag D, Harinasuta T. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull WHO 1994 ; 72 : 83-7.
46. Na-Bangchang K, Karbwang J, Molunto P, Banmairuroi V, Thanavibul A. Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. Fundam Clin Pharmacol 1995 ; 9 : 576-82.
47. Karbwang J, Na-Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994 ; 27 : 104-19.
48. Ohrt C, Watt G, Teja-Isavadharm R Keeratithakul D, Loesuttiviboon L, Webster HK, et al. Pharmacokinetics of an extended-dose halofantrine regimen in patients with malaria and in healthy volunteers. Clin Pharmacol Ther 1995 ; 57 : 525-32.
49. Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995 ; 40 : 369-78.
50. Bouchaud O, Basco LK, Gillotin C, Gimenez F, Ramiliarisoa O, Genissel B, et al. Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in non immune patients. Am J Trop Med Hyg 1994; 51 : 204-13.
51. Touze JE, Bernard J, Keundjian A, Imbert P, Viguier A, Chaudet H, et al. Electrocardiographic changes and halofantrine plasma levels during acute falciparum malaria. Am J Trop Med Hyg 1996 ; 54 : 225-8.
52. Touze JE, Perret JL, Nicolas X, Fourcade L, Bernard J, Keundjian A, et al. Efficacy of low-dose halofantrine for second treatment of uncomplicated falciparum malaria. Lancet 1997 ; 349 : 255-6.
53. Nosten F, Ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993 ; 341 : 1054-6.
54. Matson PA, Luby SP, Redd SC, Rolka HR, Meriwether RA. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996 ; 54 : 229-31.
55. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, et al. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995 ; 89 : 430-3.
56. Touze JE, Peyron F, Mojon M, Fourcade L. Halofantrine : pour de nouvelles règles de prescription. Presse Méd 1995 ; 24 : 366-9.
57. Touze JE, Heno P, Fourcade L, N'guyen H. Accès palustre simple. Rev Prat 1998 ; 48 : 268-72.
58. Hien TT, White NJ. Qinghaosu. Lancet 1993 ; 341 : 603-8.
59. De Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996 ; 52 : 818-36.
60. Teja-Isavadharm P, Nosten F, Kyle DE, Luxemburger C, Ter Kuile F, Peggins JO, et al. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J Clin Pharmacol 1996 ; 42 : 599-604.
61. Benakis A, Paris M. Loutan L, Plessas CT, Plessas ST. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am J Trop Med Hyg 1997 ; 56 : 17-23.
62. Navaratnan V, Mordi MN, Mansor SM. Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr 1997 ; 692 : 157-62.
63. De Vries PJ, Tran KD, Nguyen XK, Le Nguyen B, Pham TT, Dao DD, et al. The pharmacokinetics of a single oral dose of artemisinin in patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 1997 ; 56 : 503-7.
64. Ambroise-Thomas P. Nouveaux médicaments antipaludiques. Rev Prat 1998 ; 48 : 287-90.
65. Batty KT, Thu LT, Davis TM, Ilett KF, Mai TX, Hung NC, et al. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br J Clin Pharmacol 1998 ; 45 : 123-9.
66. Kapusnik-Uner JE, Sande MA, Chambers HF. Antimicrobial agents. In: Hardman JG, Limbird LE. Goodman and Gilman's. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill: 1996. p. 965-85.
67. Helsby NA, Edwards G, Breckenridge AM, Ward SA. The multiple dose pharmacokinetics of proguanil. Br J Clin Pharmacol 1993 ; 35 : 653-6.
68. Bygbjerg I, Ravn P, Ronn A, Flachs H, Hvidberg EF. Human pharmacokinetics of proguanil and its metabolites. Trop Med Parasitol 1987 ; 38 : 77-80.
69. Touze JE, Keundjian A, Fusai T, Doury JC. Human pharmacokinetics of chloroquine and proguanil delivered in a single capsule for malaria chemoprophylaxis. Trop Med Parasitol 1995 ; 46 : 158-60.
70. Mansor SM, Navaratnam V, Mohamad M, Hussein S, Kumar A, Jamaludin A, et al. Single dose kinetic sudy of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef®) in healthy male volunteers. Br J Clin Pharmacol 1989 ; 27 : 381-6.
71. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996 ; 347 : 1511-4.
72. Hussein Z, Eaves J, Hutchinson D, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997 ; 61 : 518-30.